Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Am J Reprod Immunol ; 92(2): e13916, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39166450

RESUMEN

BACKGROUND: Uterine endometrial cancer (UEC) is a common gynecological estrogen-dependent carcinoma, usually accompanied by intermenstrual bleeding. Active heme metabolism frequently plays an increasingly important role in many diseases, especially in cancers. Tumor-associated macrophages (TAMs) are the major population in the immune microenvironment of UEC. However, the roles of heme metabolisms in the crosstalk between UEC cells (UECCs) and macrophages are unclear. MATERIALS AND METHODS: In our study, by using TCGA database analysis, integration analysis of the protein-protein interaction (PPI) network and sample RNA transcriptome sequencing were done. The expression level of both heme-associated molecules and iron metabolism-related molecules were measured by quantitative real-time polymerase chain reaction. Heme level detection was done through dehydrohorseradish peroxidase assay. In addition to immunohistochemistry, phagocytosis assay of macrophages, immunofluorescence staining, intracellular ferrous iron staining, as well as enzyme-linked immune sorbent assay were performed. RESULTS: In the study, we verified that heme accumulation in UECCs is apparently higher than in endometrial epithelium cells. Low expression of succinate dehydrogenase B under the regulation of estrogen contributes to over-production of succinate and heme accumulation in UECC. More importantly, excessive heme in UECCs impaired macrophage phagocytosis by regulation of CD36. Mechanistically, this process is dependent on toll-like receptor (TLR4)/type I interferons alpha (IFN Iα) regulatory axis in macrophage. CONCLUSION: Collectively, these findings elucidate that active heme metabolism of UECCs directly decreases phagocytosis by controlling the secretion of TLR4-mediated IFN Iα and the expression of CD36, and further contributing to the immune escape of UEC.


Asunto(s)
Antígenos CD36 , Neoplasias Endometriales , Hemo , Interferón Tipo I , Fagocitosis , Transducción de Señal , Receptor Toll-Like 4 , Femenino , Humanos , Receptor Toll-Like 4/metabolismo , Hemo/metabolismo , Neoplasias Endometriales/inmunología , Neoplasias Endometriales/metabolismo , Interferón Tipo I/metabolismo , Antígenos CD36/metabolismo , Macrófagos/inmunología , Macrófagos/metabolismo , Microambiente Tumoral/inmunología
2.
Am J Reprod Immunol ; 91(5): e13855, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38745499

RESUMEN

Endometriosis (EM) is one of the diseases related to retrograded menstruation and hemoglobin. Heme, released from hemoglobin, is degraded by heme oxygenase-1 (HO-1). In EM lesions, heme metabolites regulate processes such as inflammation, redox balance, autophagy, dysmenorrhea, malignancy, and invasion, where macrophages (Mø) play a fundamental role in their interactions. Regulation occurs at molecular, cellular, and pathological levels. Numerous studies suggest that heme is an indispensable component in EM and may contribute to its pathogenesis. The regulatory role of heme in EM encompasses cytokines, signaling pathways, and kinases that mediate cellular responses to external stimuli. HO-1, a catalytic enzyme in the catabolic phase of heme, mitigates heme's cytotoxicity in EM due to its antioxidant, anti-inflammatory, and anti-proliferative properties. Certain compounds may intervene in EM by targeting heme metabolism, guiding the development of appropriate treatments for all stages of endometriosis.


Asunto(s)
Endometriosis , Hemo-Oxigenasa 1 , Hemo , Endometriosis/metabolismo , Endometriosis/tratamiento farmacológico , Femenino , Humanos , Hemo/metabolismo , Hemo-Oxigenasa 1/metabolismo , Animales , Transducción de Señal , Macrófagos/metabolismo , Macrófagos/inmunología , Autofagia , Citocinas/metabolismo
3.
Biomolecules ; 13(7)2023 07 10.
Artículo en Inglés | MEDLINE | ID: mdl-37509133

RESUMEN

Uterine endometrial cancer (UEC) is an estrogen-related tumor. Succinate and heme metabolism play important roles in the progression of multiple tumors. However, the relationship between estrogen, succinate, and heme metabolism and related regulatory mechanisms remain largely unknown. In this study, we observed that the expression of aminolevulinate delta synthase 1 (ALAS1) and solute carrier family member 38 (SLC25A38) in UEC tissues is significantly higher than that in normal tissues. Further analysis showed that estrogen and succinate increased the expression of ALAS1 and SLC25A38 in uterine endometrial cancer cells (UECC), and the administration of succinate upregulated the level of the estrogen receptor (ER). Silencing nuclear receptor coactivator 1 (NCOA1) reversed the effects of estrogen and succinate via downregulation of ALAS1 expression. Additionally, exposure of UECC to heme increased cell viability and invasiveness, while silencing the NCOA1 gene weakened this effect. These findings revealed that estrogen and succinate can synergistically increase the expression of ALAS1 and SLC25A38 via the ERß/NCOA1 axis, promoting heme accumulation and increasing the proliferative and invasive potential of UECC.


Asunto(s)
Neoplasias Endometriales , Ácido Succínico , Femenino , Humanos , Hemo , Estrógenos/farmacología , Neoplasias Endometriales/metabolismo , Receptores de Estrógenos , Ácido Aminolevulínico
4.
Front Oncol ; 12: 933827, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35992779

RESUMEN

Glucose is of great importance in cancer cellular metabolism. Working together with several glucose transporters (GLUTs), it provides enough energy for biological growth. The main glucose transporters in endometrial cancer (EC) are Class 1 (GLUTs 1-4) and Class 3 (GLUTs 6 and 8), and the overexpression of these GLUTs has been observed. Apart from providing abundant glucose uptake, these highly expressed GLUTs also participate in the activation of many crucial signaling pathways concerning the proliferation, angiogenesis, and metastasis of EC. In addition, overexpressed GLUTs may also cause endometrial cancer cells (ECCs) to be insensitive to hormone therapy or even resistant to radiotherapy and chemoradiotherapy. Therefore, GLUT inhibitors may hopefully become a sensitizer for EC precision-targeted therapies. This review aims to summarize the expression regulation, function, and therapy sensitivity of GLUTs in ECCs, aiming to provide a new clue for better diagnosis and treatment of EC.

5.
J Reprod Immunol ; 153: 103693, 2022 09.
Artículo en Inglés | MEDLINE | ID: mdl-35987137

RESUMEN

Intrauterine adhesion (IUA) is a fibrotic disease, with complex and multifactorial process, causing menstrual disorders, pregnancy loss or infertility. LIGHT (also named TNFSF14), mainly expressed by immune cells, has been reported to be associated with tissue fibrosis. However, the features of immunocyte subsets, the expression and roles of LIGHT and its receptor HVEM (herpes virus entry mediator) and LTßR (lymphotoxin beta receptor) in IUA remain largely unknown. Compared with the control group, we observed increased ratios of CD45+ cells, neutrophils, T cells, macrophages and decreased natural killer cells proportion, and high LIGHT expression on CD4+ T cells and macrophages in IUA endometrium. Further analysis showed there was a positive correlation between upregulated profibrotic factors (e.g., ɑ-smooth muscle actin, transforming growth factor ß1) and HVEM in IUA endometrial tissue. More importantly, recombinant human LIGHT protein directly up-regulated the expression of HVEM, LTßR, profibrotic and proinflammatory factors expression in human endometrial stromal cells. These findings reveal abnormal changes of immune cell subsets proportion and the overexpression of LIGHT-HVEM/LTßR axis in IUA endometrium, should contribute to inflammation and fibrosis formation of IUA.


Asunto(s)
Receptor beta de Linfotoxina , Miembro 14 de Receptores del Factor de Necrosis Tumoral , Miembro 14 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral , Enfermedades Uterinas , Actinas , Femenino , Fibrosis/genética , Humanos , Receptor beta de Linfotoxina/genética , Receptor beta de Linfotoxina/fisiología , Embarazo , Miembro 14 de Receptores del Factor de Necrosis Tumoral/genética , Transducción de Señal , Factor de Crecimiento Transformador beta1 , Miembro 14 de la Superfamilia de Ligandos de Factores de Necrosis Tumoral/genética , Enfermedades Uterinas/genética , Enfermedades Uterinas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA